South African pharma trade group says NHI cost plan beyond health system resources

26 March 2010

While South Africa's Ministerial Advisory Committee on National Health Insurance (NHI) continues to meet, there is still no government document on the NHI proposals available in the public domain and public comment on the NHI proposals has not yet been called for, says the pharmaceutical trade group Innovative Medicines South Africa (IMSA).

When the legislation was presented last fall, it was said that the public will have very little time to comment on the proposed NHI scheme, yet the government wants to enact laws to introduce the NHI by April this year, according to Deputy Health Minister Molefi Sefularo at the time.

The IMSA notes that ECONEX has released the seventh in its series of NHI briefing notes, titled 'Estimating the Financial Cost of the NHI Plan'. ECONEX says 'In this note we calculate the overall cost of implementing a plan with the essential features of the current NHI proposal. It is shown that the resources required for such a plan exceed the available human and physical capacity of our current health system and will put enormous strain on the fiscus.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical